Samsung Bioepis announces encouraging results for Herceptin biosimilar

1 June 2018
biosimilars_samples_large

As the American Society for Clinical Oncology (ASCO) conference got underway on Friday, Samsung Bioepis revealed the results of a one-year follow-up study on SB3, its biosimilar alternative to Roche's (ROG: SIX) blockbuster breast and stomach cancer treatment Herceptin (trastuzumab).

The study, which followed patients with early or locally advanced breast cancer, found no statistically-significant difference in mortality between SB3 and its reference biologic.

“The additional one-year follow-up study demonstrates the long-term safety profile of SB3,” said Chul Kim, head of the clinical sciences division at Samsung Bioepis, a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB) that was only formally founded in 2012.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars